ADPT
Adaptive Biotechnologies Corporation
Price Chart
Latest Quote
$18.39
Current Price| Previous Close | $18.50 |
| Open | $18.29 |
| Day High | $18.88 |
| Day Low | $18.13 |
| Volume | 2,249,036 |
Stock Information
| Shares Outstanding | 152.67M |
| Total Debt | $213.64M |
| Cash Equivalents | $212.77M |
| Revenue | $252.75M |
| Net Income | $-79.61M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.81B |
| EPS (TTM) | $-0.52 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 9/42| Debt to Equity | 0.44 |
| Debt to Earnings | 0.84 |
| Current Ratio | 2.89 |
| Quick Ratio | 2.69 |
| Avg Revenue Growth | 3.99% |
| Profit Margin | -89.12% |
| Return on Equity | -78.68% |
| Avg FCF Growth | -15.29% |
| FCF Yield | -3.52% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $18.39 | 2,249,036 |
| 2026-01-30 | $18.50 | 1,882,100 |
| 2026-01-29 | $18.37 | 1,547,400 |
| 2026-01-28 | $18.50 | 1,964,700 |
| 2026-01-27 | $19.23 | 1,377,600 |
| 2026-01-26 | $19.12 | 1,263,500 |
| 2026-01-23 | $18.55 | 1,342,800 |
| 2026-01-22 | $19.06 | 2,240,500 |
| 2026-01-21 | $17.57 | 1,668,100 |
| 2026-01-20 | $17.87 | 2,119,800 |
| 2026-01-16 | $17.52 | 1,042,600 |
| 2026-01-15 | $17.78 | 1,036,900 |
| 2026-01-14 | $18.04 | 1,866,000 |
| 2026-01-13 | $18.07 | 1,847,200 |
| 2026-01-12 | $18.26 | 3,587,900 |
| 2026-01-09 | $15.76 | 2,469,000 |
| 2026-01-08 | $15.96 | 2,074,100 |
| 2026-01-07 | $16.73 | 2,069,300 |
| 2026-01-06 | $16.11 | 3,352,300 |
| 2026-01-05 | $16.17 | 3,424,800 |
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
📰 Latest News
Assessing Adaptive Biotechnologies (ADPT) Valuation After Strong Recent Share Price Momentum
Simply Wall St. • 2026-01-14T21:10:02Z
Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026
MarketBeat • 2026-01-13T02:06:44Z
How Investors Are Reacting To Adaptive Biotechnologies (ADPT) clonoSEQ Data Shaping MRD-Guided Cancer Care
Simply Wall St. • 2025-12-15T11:07:50Z
Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake
Insider Monkey • 2025-12-08T07:16:14Z
Assessing Adaptive Biotechnologies (ADPT) Valuation After a 179% One-Year Rebound and Recent Pullback
Simply Wall St. • 2025-12-04T03:18:06Z
Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here’s Why
Insider Monkey • 2025-11-22T15:10:32Z
Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3
Insider Monkey • 2025-11-17T14:05:00Z
Adaptive Biotechnologies (ADPT) Surges to First Profit and Lifts Guidance—Has the Investment Case Evolved?
Simply Wall St. • 2025-11-07T06:25:45Z
Cathie Wood Loads Up Pinterest After Sell-Off -- Dumps Shopify, Roku, and Robinhood
GuruFocus.com • 2025-11-06T12:05:42Z
Adaptive Biotechnologies Corp (ADPT) Q3 2025 Earnings Call Highlights: Record Revenue Growth ...
GuruFocus.com • 2025-11-06T05:03:53Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $54,527,000 | $55,021,000 | $38,688,000 | $37,047,000 |
| Cost Of Revenue | $72,080,000 | $75,553,000 | $57,909,000 | $49,301,000 |
| Total Revenue | $178,957,000 | $170,276,000 | $185,308,000 | $154,344,000 |
| Operating Revenue | $178,957,000 | $170,276,000 | $185,308,000 | $154,344,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $11,580,000 | $13,800,000 | $4,238,000 | $0 |
| Total Expenses | $334,301,000 | $371,882,000 | $385,494,000 | $363,310,000 |
| Other Income Expense | $-7,205,000 | $-25,429,000 | - | - |
| Net Non Operating Interest Income Expense | $2,954,000 | $1,731,000 | $-182,000 | $1,668,000 |
| Interest Expense Non Operating | $11,580,000 | $13,800,000 | $4,238,000 | $0 |
| Operating Expense | $262,221,000 | $296,329,000 | $327,585,000 | $314,009,000 |
| Selling And Marketing Expense | $84,759,000 | $88,579,000 | $95,603,000 | $95,465,000 |
| General And Administrative Expense | $72,806,000 | $83,934,000 | $88,527,000 | $74,502,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-159,492,000 | $-225,250,000 | $-200,191,000 | $-207,279,000 |
| Net Interest Income | $2,954,000 | $1,731,000 | $-182,000 | $1,668,000 |
| Interest Income | $14,534,000 | $15,531,000 | $4,056,000 | $1,668,000 |
| Normalized Income | $-152,287,000 | $-199,821,000 | $-200,191,000 | $-207,279,000 |
| Net Income From Continuing And Discontinued Operation | $-159,492,000 | $-225,250,000 | $-200,191,000 | $-207,279,000 |
| Total Operating Income As Reported | $-162,549,000 | $-227,035,000 | $-200,186,000 | $-208,966,000 |
| Net Income Common Stockholders | $-159,492,000 | $-225,250,000 | $-200,191,000 | $-207,279,000 |
| Net Income | $-159,492,000 | $-225,250,000 | $-200,191,000 | $-207,279,000 |
| Net Income Including Noncontrolling Interests | $-159,595,000 | $-225,304,000 | $-200,368,000 | $-207,298,000 |
| Net Income Continuous Operations | $-159,595,000 | $-225,304,000 | $-200,368,000 | $-207,298,000 |
| Pretax Income | $-159,595,000 | $-225,304,000 | $-200,368,000 | $-207,298,000 |
| Special Income Charges | $-7,205,000 | $-25,429,000 | $0 | $0 |
| Interest Income Non Operating | $14,534,000 | $15,531,000 | $4,056,000 | $1,668,000 |
| Operating Income | $-155,344,000 | $-201,606,000 | $-200,186,000 | $-208,966,000 |
| Depreciation Amortization Depletion Income Statement | $1,703,000 | $1,699,000 | $1,699,000 | $1,699,000 |
| Depreciation And Amortization In Income Statement | $1,703,000 | $1,699,000 | $1,699,000 | $1,699,000 |
| Amortization Of Intangibles Income Statement | $1,703,000 | $1,699,000 | $1,699,000 | $1,699,000 |
| Gross Profit | $106,877,000 | $94,723,000 | $127,399,000 | $105,043,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-1.08 | $-1.56 | $-1.40 | $-1.48 |
| Basic EPS | $-1.08 | $-1.56 | $-1.40 | $-1.48 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-121,554,000 | $-163,844,000 | $-175,210,000 | $-193,345,000 |
| Total Unusual Items | $-7,205,000 | $-25,429,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $-7,205,000 | $-25,429,000 | $0 | $0 |
| Reconciled Depreciation | $19,256,000 | $22,231,000 | $20,920,000 | $13,953,000 |
| EBITDA (Bullshit earnings) | $-128,759,000 | $-189,273,000 | $-175,210,000 | $-193,345,000 |
| EBIT | $-148,015,000 | $-211,504,000 | $-196,130,000 | $-207,298,000 |
| Diluted Average Shares | $147,101,648 | $144,383,294 | $142,515,917 | $140,354,915 |
| Basic Average Shares | $147,101,648 | $144,383,294 | $142,515,917 | $140,354,915 |
| Diluted NI Availto Com Stockholders | $-159,492,000 | $-225,250,000 | $-200,191,000 | $-207,279,000 |
| Minority Interests | $103,000 | $54,000 | $177,000 | $19,000 |
| Impairment Of Capital Assets | $7,205,000 | $25,429,000 | $0 | $0 |
| Amortization | $1,703,000 | $1,699,000 | $1,699,000 | $1,699,000 |
| Research And Development | $102,953,000 | $122,117,000 | $141,756,000 | $142,343,000 |
| Selling General And Administration | $157,565,000 | $172,513,000 | $184,130,000 | $169,967,000 |
| Other Gand A | $72,806,000 | $83,934,000 | $88,527,000 | $74,502,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $80,312,000 | $184,299,000 | $338,366,000 | $476,494,000 |
| Total Assets | $539,376,000 | $661,134,000 | $856,617,000 | $923,344,000 |
| Total Non Current Assets | $255,624,000 | $250,946,000 | $294,471,000 | $520,596,000 |
| Other Non Current Assets | $5,184,000 | $6,523,000 | $4,462,000 | $3,013,000 |
| Investmentin Financial Assets | $33,660,000 | $0 | $0 | $217,145,000 |
| Goodwill And Other Intangible Assets | $122,397,000 | $124,100,000 | $125,799,000 | $127,498,000 |
| Other Intangible Assets | $3,425,000 | $5,128,000 | $6,827,000 | $8,526,000 |
| Current Assets | $283,752,000 | $410,188,000 | $562,146,000 | $402,748,000 |
| Other Current Assets | $11,287,000 | $11,370,000 | $9,440,000 | $13,015,000 |
| Inventory | $8,440,000 | $14,448,000 | $14,453,000 | $19,263,000 |
| Receivables | $41,731,000 | $37,969,000 | $40,057,000 | $17,409,000 |
| Accounts Receivable | $41,731,000 | $37,969,000 | $40,057,000 | $17,409,000 |
| Cash Cash Equivalents And Short Term Investments | $222,294,000 | $346,401,000 | $498,196,000 | $353,061,000 |
| Cash And Cash Equivalents | $47,920,000 | $65,064,000 | $90,030,000 | $139,065,000 |
| Prepaid Assets | - | - | - | $13,015,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $89,387,000 | $98,772,000 | $108,002,000 | $111,740,000 |
| Long Term Debt And Capital Lease Obligation | $79,148,000 | $89,388,000 | $98,772,000 | $106,685,000 |
| Current Debt And Capital Lease Obligation | $10,239,000 | $9,384,000 | $9,230,000 | $5,055,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $336,891,000 | $352,856,000 | $392,519,000 | $319,242,000 |
| Total Non Current Liabilities Net Minority Interest | $238,838,000 | $264,841,000 | $282,731,000 | $205,435,000 |
| Other Non Current Liabilities | $132,434,000 | $130,660,000 | $125,360,000 | - |
| Non Current Deferred Liabilities | $27,256,000 | $44,793,000 | $58,599,000 | $98,750,000 |
| Current Liabilities | $98,053,000 | $88,015,000 | $109,788,000 | $113,807,000 |
| Other Current Liabilities | $865,000 | - | - | - |
| Current Deferred Liabilities | $55,689,000 | $48,630,000 | $64,115,000 | $80,460,000 |
| Payables And Accrued Expenses | $15,422,000 | $16,316,000 | $20,508,000 | $12,650,000 |
| Payables | $7,441,000 | $7,778,000 | $8,278,000 | $3,698,000 |
| Total Tax Payable | $176,000 | $59,000 | $194,000 | $391,000 |
| Accounts Payable | $7,265,000 | $7,719,000 | $8,084,000 | $3,307,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $202,709,000 | $308,399,000 | $464,165,000 | $603,992,000 |
| Total Equity Gross Minority Interest | $202,485,000 | $308,278,000 | $464,098,000 | $604,102,000 |
| Stockholders Equity | $202,709,000 | $308,399,000 | $464,165,000 | $603,992,000 |
| Gains Losses Not Affecting Retained Earnings | $166,000 | $215,000 | $-4,116,000 | $-1,137,000 |
| Other Equity Adjustments | $166,000 | $215,000 | $-4,116,000 | $-1,137,000 |
| Retained Earnings | $-1,303,824,000 | $-1,144,332,000 | $-919,082,000 | $-718,891,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $147,773,744 | $145,082,271 | $143,105,002 | $141,393,865 |
| Share Issued | $147,773,744 | $145,082,271 | $143,105,002 | $141,393,865 |
| Tangible Book Value | $80,312,000 | $184,299,000 | $338,366,000 | $476,494,000 |
| Invested Capital | $202,709,000 | $308,399,000 | $464,165,000 | $603,992,000 |
| Working Capital | $185,699,000 | $322,173,000 | $452,358,000 | $288,941,000 |
| Capital Lease Obligations | $89,387,000 | $98,772,000 | $108,002,000 | $111,740,000 |
| Total Capitalization | $202,709,000 | $308,399,000 | $464,165,000 | $603,992,000 |
| Minority Interest | $-224,000 | $-121,000 | $-67,000 | $110,000 |
| Additional Paid In Capital | $1,506,353,000 | $1,452,502,000 | $1,387,349,000 | $1,324,006,000 |
| Capital Stock | $14,000 | $14,000 | $14,000 | $14,000 |
| Common Stock | $14,000 | $14,000 | $14,000 | $14,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $27,256,000 | $44,793,000 | $58,599,000 | $98,750,000 |
| Long Term Capital Lease Obligation | $79,148,000 | $89,388,000 | $98,772,000 | $106,685,000 |
| Current Deferred Revenue | $55,689,000 | $48,630,000 | $64,115,000 | $80,460,000 |
| Current Capital Lease Obligation | $10,239,000 | $9,384,000 | $9,230,000 | $5,055,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $15,838,000 | $13,685,000 | $15,935,000 | $15,642,000 |
| Current Accrued Expenses | $7,981,000 | $8,538,000 | $12,230,000 | $8,952,000 |
| Investments And Advances | $33,660,000 | $0 | $0 | $217,145,000 |
| Available For Sale Securities | $33,660,000 | - | - | $217,145,000 |
| Goodwill | $118,972,000 | $118,972,000 | $118,972,000 | $118,972,000 |
| Net PPE | $94,383,000 | $120,323,000 | $164,210,000 | $172,940,000 |
| Accumulated Depreciation | $-87,817,000 | $-73,234,000 | $-54,350,000 | $-36,226,000 |
| Gross PPE | $182,200,000 | $193,557,000 | $218,560,000 | $209,166,000 |
| Leases | $73,277,000 | $74,734,000 | $72,403,000 | $65,959,000 |
| Construction In Progress | $2,571,000 | $3,405,000 | $7,625,000 | $5,658,000 |
| Other Properties | $92,717,000 | $101,663,000 | $124,355,000 | $123,990,000 |
| Machinery Furniture Equipment | $13,635,000 | $13,755,000 | $14,177,000 | $13,559,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $174,374,000 | $281,337,000 | $408,166,000 | $213,996,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-98,876,000 | $-167,021,000 | $-200,294,000 | $-254,473,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-95,212,000 | $-156,324,000 | $-183,945,000 | $-192,727,000 |
| Cash Flow From Continuing Operating Activities | $-95,212,000 | $-156,324,000 | $-183,945,000 | $-192,727,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-3,664,000 | $-10,697,000 | $-16,349,000 | $-61,746,000 |
| Investing Cash Flow | $77,792,000 | $129,647,000 | $2,905,000 | $181,210,000 |
| Cash Flow From Continuing Investing Activities | $77,792,000 | $129,647,000 | $2,905,000 | $181,210,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Financing Cash Flow | $241,000 | $2,245,000 | $132,265,000 | $27,146,000 |
| Cash Flow From Continuing Financing Activities | $241,000 | $2,245,000 | $132,265,000 | $27,146,000 |
| Issuance Of Capital Stock | - | - | $0 | $0 |
| Net Other Financing Charges | - | - | $124,375,000 | $429,000 |
| Net Common Stock Issuance | - | - | $0 | $0 |
| Common Stock Issuance | - | - | $0 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Paid Supplemental Data | $8,864,000 | $8,985,000 | $494,000 | $0 |
| End Cash Position | $50,817,000 | $67,996,000 | $92,428,000 | $141,203,000 |
| Beginning Cash Position | $67,996,000 | $92,428,000 | $141,203,000 | $125,574,000 |
| Changes In Cash | $-17,179,000 | $-24,432,000 | $-48,775,000 | $15,629,000 |
| Proceeds From Stock Option Exercised | $241,000 | $2,245,000 | $7,890,000 | $26,717,000 |
| Net Investment Purchase And Sale | $81,456,000 | $140,344,000 | $19,254,000 | $242,956,000 |
| Sale Of Investment | $325,713,000 | $569,902,000 | $298,032,000 | $559,500,000 |
| Purchase Of Investment | $-244,257,000 | $-429,558,000 | $-278,778,000 | $-316,544,000 |
| Net PPE Purchase And Sale | $-3,664,000 | $-10,697,000 | $-16,349,000 | $-61,746,000 |
| Purchase Of PPE | $-3,664,000 | $-10,697,000 | $-16,349,000 | $-61,746,000 |
| Change In Working Capital | $-17,454,000 | $-46,183,000 | $-71,546,000 | $-56,816,000 |
| Change In Other Working Capital | $-19,836,000 | $-38,040,000 | $-60,377,000 | $-49,480,000 |
| Change In Payables And Accrued Expense | $671,000 | $-5,407,000 | $7,111,000 | $3,940,000 |
| Change In Prepaid Assets | $83,000 | $-1,930,000 | $3,551,000 | $1,286,000 |
| Change In Inventory | $5,372,000 | $-2,838,000 | $817,000 | $-5,200,000 |
| Change In Receivables | $-3,744,000 | $2,032,000 | $-22,648,000 | $-7,362,000 |
| Changes In Account Receivables | $-3,744,000 | $2,032,000 | $-22,648,000 | $-7,362,000 |
| Other Non Cash Items | $8,036,000 | $12,392,000 | $8,193,000 | $6,950,000 |
| Stock Based Compensation | $53,610,000 | $62,908,000 | $55,477,000 | $43,251,000 |
| Provisionand Write Offof Assets | $1,938,000 | $1,387,000 | $2,638,000 | $0 |
| Asset Impairment Charge | $7,205,000 | $25,429,000 | $0 | $0 |
| Amortization Of Securities | $-8,208,000 | $-9,184,000 | $741,000 | $7,233,000 |
| Depreciation Amortization Depletion | $19,256,000 | $22,231,000 | $20,920,000 | $13,953,000 |
| Depreciation And Amortization | $19,256,000 | $22,231,000 | $20,920,000 | $13,953,000 |
| Amortization Cash Flow | $1,703,000 | $1,699,000 | $1,699,000 | $1,699,000 |
| Amortization Of Intangibles | $1,703,000 | $1,699,000 | $1,699,000 | $1,699,000 |
| Depreciation | $17,553,000 | $20,532,000 | $19,221,000 | $12,254,000 |
| Net Income From Continuing Operations | $-159,595,000 | $-225,304,000 | $-200,368,000 | $-207,298,000 |
| Issuance Of Debt | - | - | $124,375,000 | $0 |
| Net Issuance Payments Of Debt | - | - | $124,375,000 | $0 |
| Net Long Term Debt Issuance | - | - | $124,375,000 | $0 |
| Long Term Debt Issuance | - | - | $124,375,000 | $0 |